INGELHEIM, Germany & INDIANAPOLIS, Ind. - Thursday, September 17th 2015 [ME NewsWire]
Jardiance® achieved superiority for the primary CV endpoint and a significant reduction in CV death in people with T2D at high risk of CV events
The results of the EMPA-REG OUTCOME® trial were published in NEJM and also presented at the 51st European Association for the Study of Diabetes Annual Meeting today
(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company’s (NYSE: LLY) Jardiance® (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14 percent when added to standard of care, in patients with type 2 diabetes (T2D) at high risk of CV events. There was a 38 percent reduction in CV death, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke.
In addition, treatment with Jardiance® resulted in a lower risk of all-cause mortality (32 percent reduction) and hospitalization for heart failure (35 percent reduction).
“These results are both novel and exciting for the millions of people living with type 2 diabetes at risk for cardiovascular disease. Addressing the burden of cardiovascular events, including death, is at the core of diabetes care, and until now no single diabetes medication has been associated with a reduction in mortality,” said lead investigator of the trial Dr. Bernard Zinman, Director, Diabetes Centre, Mount Sinai Hospital; Senior Scientist, Lunenfeld Tanenbaum Research Institute, and Professor of Medicine, University of Toronto, Canada. “In this study, empagliflozin was shown to prevent one out of three cardiovascular deaths.”
Life expectancy of people with T2D at high CV risk is, on average, decreased by up to twelve years1 with approximately 50 percent of deaths in people with T2D caused by CV disease.2,3 The effect of Jardiance® in this trial was observed on top of standard of care. This means the benefit was seen over and above other treatments patients were already receiving for diabetes and/or cardiovascular disease (such as blood pressure and cholesterol lowering-medications).
“The EMPA-REG OUTCOME trial results are encouraging for healthcare professionals and their patients,” said Dr. Christopher P. Cannon, Cardiovascular Division, Brigham and Women's Hospital and Professor of Medicine, Harvard Medical School, who was not involved in the study. “Patients in the study were already being treated with medications that have been proven to reduce cardiovascular events. The observation that empagliflozin provided additional cardiovascular death reduction on top of these other medications is a very important finding.”
The overall safety profile of Jardiance® was consistent with previous trials. The incidence of diabetic ketoacidosis was at or below 0.1 percent and similar across all treatment groups.
These data were presented today at the 51st European Association for the Study of Diabetes Annual Meeting in Stockholm, Sweden, and simultaneously published in the New England Journal of Medicine.
“The Boehringer Ingelheim and Lilly Diabetes Alliance is very pleased to share the results of the EMPA-REG OUTCOME® trial with the healthcare community,” said Prof. Hans-Juergen Woerle, Global Vice President Medicine, Boehringer Ingelheim. “Cardiovascular disease is the number one cause of death in people with type 2 diabetes worldwide and reducing cardiovascular risk, including death, is an essential component of diabetes management.”
About EMPA-REG OUTCOME®
EMPA-REG OUTCOME® was a long-term, multicentre, randomised, double-blind, placebo-controlled trial that involved more than 7,000 patients from 42 countries with type 2 diabetes at high risk for cardiovascular events. There were 772 primary outcome events in the EMPA-REG OUTCOME® trial over a median observation period of 3.1 years.
The study was designed to assess the effect of Jardiance® (10mg or 25mg once daily) added to standard of care compared with placebo added to standard of care. The primary endpoint was defined as time to first occurrence of either CV death, or non-fatal heart attack or non-fatal stroke. The study was designed to first test for non-inferiority and then for superiority.
Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including blood pressure and cholesterol-lowering medications).
Of the 7,020 treated patients, more than 97 percent completed the trial and vital status was available for more than 99 percent of these patients at study end. Analyses and results were independently validated and confirmed by the University of Freiburg, Germany an internationally renowned Academic Centre specializing in statistical analyses.
Jardiance® (empagliflozin) is an oral, once daily, highly selective sodium glucose co-transporter 2 (SGLT2) inhibitor approved for use in Europe, the United States and other markets around the world for the treatment of adults with type 2 diabetes.
Jardiance® works by blocking the reabsorption of glucose (blood sugar) by the kidney, leading to urinary glucose excretion, and lowering blood glucose levels in people with type 2 diabetes. SGLT2 inhibition targets glucose directly and works independently of β-cell function and the insulin pathway.
Jardiance® is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).
This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.
Please click on the link below for ‘Notes to Editors’ and ‘References’:
View this news release and multimedia online at: http://www.businesswire.com/news/home/20150917006090/en
Product Communication Manager
Boehringer Ingelheim GmbH
Phone: +49 (151) 689 46812
Phone: +1 (317) 478 542